Hemodialysis and blood coagulation: the effect of hemodialysis on coagulation factor XIII and thrombin-antithrombin III complex.
Blood membrane interaction during hemodialysis (HD) regularly leads to stimulation of leukocyte function and related release of granular enzymes. The present study aimed to investigate the possible influence of an HD-induced release of granulocyte elastase on blood coagulation. Therefore a highly sensitive substrate of polymorphonuclear elastase, the plasma coagulation factor XIII and its subunits A and S were determined in the course of HD. Consumption of both subunit A and S have been previously shown to be due to proteolysis by elastase, whereas a decrease in subunit A will be typical for thrombin activation. Furthermore, the thrombin-antithrombin III complex (TAT) acting as a predisposition parameter for thrombotic events was measured during HD treatment. Apart from a virtual fall in factor XIII total activity simulated by heparin, no significant HD-induced consumption of factor XIII could be observed. There was also no indication of an elastase- or thrombin-related change in subunit concentrations. Predialysis values of the TAT complex were generally elevated in HD patients, but only patients with acute renal failure showed a constant increase of TAT during HD. These findings suggest that HD patients are exposed to a latent activation of coagulation resulting in an elevated thrombogenetic risk mainly due to the underlying disease. An additional coagulatory stimulation by the HD procedure seems to be restricted to cases of acute renal failure.
Kolb
G
G
Department of Internal Medicine, Philipps-University Hospitals, Marburg, FRG.
Fischer
W
W
Seitz
R
R
Müller
T
T
Egbring
R
R
Lange
H
H
Havemann
K
K
D058186:Acute Kidney Injury / Q000628:therapy; D000990:Antithrombin III / Q000378:metabolism*; D001672:Biocompatible Materials / Q000009:adverse effects*; D002482:Cellulose / Q000009:adverse effects / Q000031:analogs & derivatives; D005176:Factor XIII / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008567:Membranes, Artificial; D010447:Peptide Hydrolases / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects*
D001672:Biocompatible Materials; D008567:Membranes, Artificial; C046193:antithrombin III-protease complex; C054645:Hemophan; D000990:Antithrombin III; D002482:Cellulose; D005176:Factor XIII; C009865:cuprammonium cellulose; D010447:Peptide Hydrolases